Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain

Zelenakas, K.; Fricke, James R.; Jayawardene, S.; Kellstein, David

doi:10.1111/j.1368-5031.2004.00156.x

Cited by 41 publications

(70 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Zelenakas et al, 2004;Fricke et al, 2008) and, to the best of our knowledge, this is the first paper to compare this drug efficacy with diclofenac, which is largely utilized in Brazilian dental treatments.…”

Section: Nícoli G A; Conte-neto N; Campos J á D B; Cabrini-mentioning

confidence: 98%

Efficacy of Lumiracoxib Versus Diclofenac Sodium in Pain Control Following Extraction of Impacted Lower Third Molar

Nícoli

Neto

Campos

et al. 2017

Int. J. Odontostomat.

View full text Add to dashboard Cite

ABSTRACT:The aim of this paper was to compare the efficacy of two different anti-inflammatory agents, Diclofenac (Deltaflogin ® ) and Lumiracoxib (Prexige ® ) in the control of postoperative pain that results from surgical removal of impacted lower third molars. Twenty adult patients from the Oral and Maxillofacial Surgery Division of the Araraquara Dentistry School, UNESP who presented bilateral impacted lower third molars were included in the study. Removal of the impacted teeth was performed in each side in different operative moments in a split mouth design for the study. The anti-inflammatory drugs evaluated were randomly administered on the first and second surgical procedures. The pain level was recorded using an analogical visual scale at 6, 24, 48 and 72 hours after surgical intervention. Both lumiracoxib 400 mg and diclofenac 100 mg are efficient for acute pain control after surgical removal of impacted lower third molars. However, lumiracoxib offered better pain control.

show abstract

Section: Nícoli G A; Conte-neto N; Campos J á D B; Cabrini-mentioning

confidence: 98%

Efficacy of Lumiracoxib Versus Diclofenac Sodium in Pain Control Following Extraction of Impacted Lower Third Molar

Nícoli

Neto

Campos

et al. 2017

Int. J. Odontostomat.

View full text Add to dashboard Cite

show abstract

“…3 Acute dental pain and postoperative pain are often treated with analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) such as paracetamol, ibuprofen, rofecoxib and celecoxib. [4][5][6] The efficacy of these drugs in reducing inflammation and pain is largely attributed to prevention of prostaglandin synthesis via non-specific inhibition of both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). 5 Lumiracoxib is a new selective inhibitor of COX-2 that was also developed for treating acute pain.…”

Section: Introductionmentioning

confidence: 99%

“…6 The second one compared lumiracoxib 400 mg with rofecoxib 50 mg, celecoxib 200 mg and placebo, and 5 The third compared lumiracoxib 400 mg with celecoxib 400 mg and placebo, and assessed 364 patients. 4 These studies were all carried out in the United States with financial support from the pharmaceutical industry.…”

mentioning

confidence: 99%

Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials

Silva¹,

Riera

Saconato

2011

Sao Paulo Med. J.

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: Lumiracoxib is an anti-inflammatory drug that has been used to treat acute dental pain, mainly in postsurgical settings, in which the greatest levels of pain and discomfort are experienced during the first 24 hours. This study aimed to assess the efficacy and safety of lumiracoxib for treating acute postsurgical dental pain. DESIGN AND SETTING: Systematic review developed at the Brazilian Cochrane Centre, Universidade Federal de São Paulo. METHODS: An electronic search was conducted in the PubMed, Cochrane Library, Lilacs (Literatura Latino-Americana e do Caribe em Ciências da Saúde), SciELO (Scientific Electronic Library Online) and Embase databases. A manual search was also performed. Only randomized controlled trials were included, and these were selected and assessed by two researchers with regard to the risk of bias. RESULTS: Three clinical trials with 921 participants were included. Lumiracoxib 400 mg produced onset of analgesia in a shorter time than shown by lumiracoxib 100 mg, celecoxib 200 mg and ibuprofen 400 mg. There was no difference between lumiracoxib 400 mg and rofecoxib 50 mg. In two studies, the mean time taken to attain onset of analgesia for the placebo was not estimated because the number of participants who reached onset was too small. CONCLUSION: There is evidence with a moderate risk of bias that recommends the use of lumiracoxib for acute postoperative dental pain. However, the adverse effects are not completely known. Given that lumiracoxib is currently available in only three countries, further studies are likely to be rare and discouraged.reSUmO CONTEXTO E OBJETIVO: O lumiracoxibe é um anti-inflamatório que tem sido utilizado no tratamento de dor dental aguda, principalmente no cenário pós-cirúrgico, no qual níveis mais elevados de dor e desconforto são sentidos durante as primeiras 24 horas. Este estudo teve por objetivo avaliar a eficácia e a segurança do lumiracoxibe no tratamento da dor dental aguda e pós-operatória.

show abstract

“…Thrombocytopenia, cutaneous eruptions, visual disturbance, fluid retention, and edema occur less frequently. 4 The aim of the present study was to assess the onset of the analgesic effect and the effectiveness and tolerability of oral treatment with a single dose of nimesulide 300 mg versus ibuprofen 400 mg q6h over 24 hours in patients with moderate or severe pain after surgical extraction of an impacted third molar.…”

Section: Introductionmentioning

confidence: 99%

“…This type of pain is widely used to evaluate the effectiveness of analgesic agents, especially in single doses. [1][2][3][4] Oral nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in relieving mild or moderate pain, and they are more likely to be used in ambulatory patients compared with their injectable counterparts. The analgesic action of nimesulide has been documented in a wide range of acute and chronic pain.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and tolerability of once-daily nimesulide versus ibuprofen in pain management after surgical extraction of an impacted third molar: A 24-hour, double-blind, randomized, double-dummy, parallel-group study

BOCANEGRA¹,

SEIJAS²,

GONZALEZYIBIRIN³

2005

Current Therapeutic Research

View full text Add to dashboard Cite

Background: Nimesulide is a nonsteroidal, anti-inflammatory drug that has been used for a wide range of acute and chronic pain. A once-daily formulation of nimesulide is now commercially available, but its effectiveness in pain management after dental surgery has not been assessed. Objective: The aim of this study was to assess the analgesic effectiveness and tolerability of oral treatment with once-daily nimesulide versus ibuprofen q6h over 24 hours in patients with postoperative pain associated with surgical extraction of an impacted third molar.Methods: This 24-hour, double-blind, randomized, double-dummy, parallelgroup study was conducted at a private practice in Caracas, Venezuela. Patients aged between 12 and 60 years with moderate to severe pain after extraction of an impacted third molar were enrolled. Patients were randomized to receive a single dose of nimesulide (300-mg tablet) or ibuprofen (400-mg tablets) q6h for 24 hours. For double-dummy design, patients in the nimesulide group also received ibuprofen placebo tablets, to be taken q6h for 24 hours, and patients in the ibuprofen group received a nimesulide placebo tablet. The primary end points were pain intensity (PI) and pain relief scores over 24 hours. Secondary end points included total pain relief, PI difference (PID), sum of PID (SPID), time to first measurable change in PI 0e, PID ~10 mm), and use of rescue medication (acetaminophen). Patients also rated the treatment's effectiveness as very poor to very good on questioning by the study investigator. Spontaneously reported adverse effects (AEs) were recorded.Results: Eighty-six patients were enrolled (56 females, 30 males), with 43 patients per treatment group (mean age: nimesulide group, 25.2 years; ibuprofen group, 24.2 years). The baseline characteristics were statistically similar between the 2 groups. Compared with baseline, mean PI scores were significantly lower in both treatment groups at all time points throughout the study (P < 0.001 PI scores were significantly lower in the nimesulide group compared with the ibuprofen group at 15 and 45 minutes and 1 hour after study drug administration (P _< 0.049). Time to first measurable change in PI was within the first 15 minutes in 22 patients (52%) in the nimesulide group and in 14 patients (33%) in the ibuprofen group (P = 0.03). Analgesia lasted 24 hours with nimesulide and ibuprofen (PI scores at 24 hours, 9.4 and 3.6, respectively). The mean PR score was significantly lower in the uimesulide group compared with the ibuprofen group at 1 hour after study drug administration (P = 0.049).Compared with baseline, PID and SPID were significantly higher in both treatment groups throughout the study (P < 0.001). Significantly more patients in the nimesulide group than in the ibuprofen group reported that treatment provided effective pain relief (82% vs 73%; P = 0.013). No AEs were reported in either treatment group throughout the study. Use of rescue medication was statistically similar between the nimesulide and ibuprofen groups (38% a...

show abstract

Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain

Cited by 41 publications

References 11 publications

Efficacy of Lumiracoxib Versus Diclofenac Sodium in Pain Control Following Extraction of Impacted Lower Third Molar

Efficacy of Lumiracoxib Versus Diclofenac Sodium in Pain Control Following Extraction of Impacted Lower Third Molar

Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials

Effectiveness and tolerability of once-daily nimesulide versus ibuprofen in pain management after surgical extraction of an impacted third molar: A 24-hour, double-blind, randomized, double-dummy, parallel-group study

Contact Info

Product

Resources

About